We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET Scan as a Screening Tool for Liver Transplant in Patients With Hepatocellular Carcinoma (HCC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01320852
First Posted: March 23, 2011
Last Update Posted: October 25, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Pfizer
Information provided by (Responsible Party):
peter metrakos, McGill University Health Center
  Purpose
This study aims at testing the utility of PET Scan as a screening tool for liver transplantation in patients with Hepatocellular Carcinoma. Patients being worked up for liver transplant for hepatocellular carcinoma will undergo a PET Scan and will be followed until 2 years after transplantation. At that time survival data will be analysed according to PET Scan results to determine if it can be used to predict outcome.

Condition Intervention
Hepatocellular Carcinoma Other: PET Scan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: PET Scan as a Screening Tool for Liver Transplant in Patients With HCC

Resource links provided by NLM:


Further study details as provided by peter metrakos, McGill University Health Center:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: up to death ]
    The primary objective of the study is to compare, according to PET scan results, the post-transplantation overall survival of patients meeting Milan criteria to those not meeting Milan criteria


Enrollment: 100
Study Start Date: December 2010
Study Completion Date: October 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Milan Criteria
Patients meeting the Milan Criteria
Other: PET Scan
All patients will have a PET scan as part of their pre-transplant assessment
No Milan Criteria
Patients not meeting the Milan Criteria
Other: PET Scan
All patients will have a PET scan as part of their pre-transplant assessment

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patient over 18 years of age
  • Diagnosis of HCC confirmed by histology if available or by two imaging modalities
  • Able to give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.

Exclusion Criteria:

  • Unable to give consent to the study
  • Unable to undergo a PET Scan
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01320852


Locations
Canada, Quebec
McGill Univeristy Health Centre
Montreal, Quebec, Canada, H3A 1A1
Sponsors and Collaborators
McGill University Health Center
Pfizer
  More Information

Responsible Party: peter metrakos, Director Multiorgan Transplant Program-MUHC, McGill University Health Center
ClinicalTrials.gov Identifier: NCT01320852     History of Changes
Other Study ID Numbers: BMD-09-209
First Submitted: December 22, 2010
First Posted: March 23, 2011
Last Update Posted: October 25, 2013
Last Verified: October 2013

Keywords provided by peter metrakos, McGill University Health Center:
Transplant

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases